Is Pharmacological Treatment With the Glucagon-like Peptide-1 Receptor Agonist Liraglutide 3mg (Saxenda®) Once-daily a Viable Treatment for Weight Management in Forensic Psychiatry Patients? A Feasibility Study.
Latest Information Update: 10 Aug 2023
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- 30 Mar 2023 Status changed to completed.
- 04 Jun 2021 Planned End Date changed from 6 Jun 2022 to 21 Dec 2022.
- 04 Jun 2021 Planned primary completion date changed from 6 Dec 2021 to 31 Mar 2022.